Intelligence Feed event · Policy · 2026-09-21

    Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets

    Question

    Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets

    Direct answer

    Ionis Pharmaceuticals has faced significant equity liquidation this year, falling more than 40% amid clinical trial headwinds in its high-profile pelacarsen and eplontersen programs. The clinical setbacks have delayed key commercialization timelines. Despite ongoing operating losses and program revisions, sell-side coverage remains largely constructive with an average price target of $83.82, highlighting residual value in the underlying RNA-targeting technology platform and pharma collaborations.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-21
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets”, revision 1, evidence through 2026-09-21. https://marketontology.com/market-events/2026-09-21/ionis-plunges-over-40-ytd-on-late-stage-setbacks-despite-bullish-targets-0bb479

    POLICY
    Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets
    Ionis Pharmaceuticals has faced significant equity liquidation this year, falling more than 40% amid clinical trial headwinds in its high-profile pelacarsen and eplontersen programs. The clinical setbacks have delayed key commercialization timelines. Despite ongoing operating losses and program revisions, sell-side coverage remains largely constructive with an average price target of $83.82, highlighting residual value in the underlying RNA-targeting technology platform and pharma collaborations.
    IONSAZN
    Impact
    65
    SEP 21
    SIG
    82%
    IONSAZN
    Ionis Plunges Over 40% YTD on Late-Stage Setbacks Despite Bullish Targets
    Ionis Pharmaceuticals has faced significant equity liquidation this year, falling more than 40% amid clinical trial headwinds in its high-profile pelacarsen and eplontersen programs. The clinical setbacks have delayed key commercialization timelines. Despite ongoing operating losses and program revisions, sell-side coverage remains largely constructive with an average price target of $83.82, highlighting residual value in the underlying RNA-targeting technology platform and pharma collaborations.
    → Pipeline trial failures in pelacarsen and eplontersen reduce projected peak risk-adjusted royalty cash flows, driving a 40% equity market cap reduction across IONS shares.
    Impact
    Ionis Pharmaceuticals has faced significant equity liquidation this year, falling more than 40% amid clinical trial headwinds in its high-profile pelacarsen and eplontersen programs. The clinical setbacks have delayed key commercialization timelines. Despite ongoing operating losses and program revisions, sell-side coverage remains largely constructive with an average price target of $83.82, highlighting residual value in the underlying RNA-targeting technology platform and pharma collaborations.
    Affected
    IONSAZN
    Transmission
    Pipeline trial failures in pelacarsen and eplontersen reduce projected peak risk-adjusted royalty cash flows, driving a 40% equity market cap reduction across IONS shares.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    IONSclinical pipeline delay and peak sales cash-flow discountingDown1-3mIonis stock has plummeted over 40% this year due to late-stage clinical trial failures.
    AZNpartnered drug commercialization timeline revisionsWatch1-4wAstraZeneca collaborates on Ionis late-stage antisense programs.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    IONSDowndisagreed44.90 2026-09-21+1.89%+1.49%Pending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month